Cellid, Co., Ltd.
Financials
Valuation Metrics
Cellid, Co., Ltd.'s Market Cap is ₩683B. At end of 2025 it was ₩844B. Ranked #1562 of 2,421 in KR market (top 65%), #918 of 1,640 on KOSDAQ (top 56%), #174 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 75%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 68.30B KRW | KR#1,562/2,421 Sec#174/231 |
| Revenue | 10.42B KRW | KR#2,287/2,421 Sec#177/231 |
| Net Income | -27.38B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 96.83B KRW | KR#1,812/2,421 Sec#143/231 |
| Net Assets | 53.67B KRW | KR#1,861/2,421 Sec#158/231 |
| Employees | 56 | KR#2,005/2,421 Sec#180/231 |
| Value | ||
| P/B | 1.27x | KR#1,668/2,421 Sec#113/231 |
| P/S | 6.55x | KR#2,207/2,421 Sec#149/231 |
| FCF Yield | -33.72% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -51.02% | KR#2,279/2,421 Sec#198/231 |
| ROA | -28.28% | KR#2,307/2,421 Sec#197/231 |
| Op. Margin | -99.30% | KR#2,301/2,421 Sec#173/231 |
| Revenue Growth | 49.87% | KR#210/2,421 Sec#30/231 |
| Financial Health | ||
| Debt Ratio | 80.41% | KR#1,355/2,421 Sec#158/231 |
| Total Debt | 33.63B KRW | KR#1,172/2,421 Sec#84/231 |
| FCF | -23.03B KRW | KR#1,926/2,421 Sec#184/231 |
| Cash | 12.98B KRW | KR#1,538/2,421 Sec#125/231 |
| Current Ratio | 0.57x | KR#2,095/2,421 Sec#199/231 |
| Performance | ||
| 1Y Return | -42.41% | KR#1,894/2,421 Sec#163/231 |
| 1M Return | 38.46% | KR#89/2,421 Sec#9/231 |
| From 52W High | -51.37% | KR#1,461/2,421 Sec#111/231 |
| 1Y MDD | -75.57% | KR#2,197/2,421 Sec#194/231 |
| Trading | ||
| Volume | 274,008 shares | KR#387/2,421 Sec#21/231 |
| Trading Value | 634.5M KRW | KR#861/2,421 Sec#86/231 |
| Foreign Own. | 0.90% | KR#2,073/2,421 Sec#202/231 |
| Per Share | ||
| EPS | -928 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,819 KRW | KR#2,102/2,421 Sec#174/231 |
Company Info
Cellid, a bio-venture established in 2006, expanded its business in 2024 by merging with ForBaker Co., Ltd. to establish an e-commerce division. The company develops CeliVax-based anti-cancer immunotherapy vaccines and adenovirus vector-based COVID-19 prophylactic vaccines, while also operating biopharmaceutical contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) services from its 2020 GMP facility. Its anti-cancer immunotherapy vaccines are undergoing clinical and non-clinical trials, and its Omicron-specific COVID-19 vaccine has completed Phase 3 administration. Cellid is headquartered in Gwanak-gu, Seoul.